Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 10/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712240 | 0.97 | DNM1 (0.70) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL21591924 | 0.90 | DNM1 (0.62) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL29712227 | 0.87 | DNM1 (0.60) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL5091705 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL305729 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL5087904 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL5088099 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL5085435 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL5086648 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB | |
| Bromide SCHEMBL5088225 | 0.87 | DNM1 (0.94) | DNM1TSHRALDH1A1BDKRB2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024756-B2 | Countercurrent rare earth separation process | Seren Technologies Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11958754-B2 | Enhanced separation of rare earth metals | Seren Technologies Limited (GB) | 2024-04-16 | — | — | US | disclosed |
| US-11401579-B2 | Rare earth metal oxide process including extracting rare earth metal from acidic solution with an ionic liquid composition | Seren Technologies Limited (GB) | 2022-08-02 | — | — | US | disclosed |
| US-20210285072-A1 | COUNTERCURRENT RARE EARTH SEPARATION PROCESS | Seren Technologies Limited (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20210254191-A1 | RARE EARTH METAL OXIDE PREPARATION | Seren Technologies Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3807242-A1 | ENHANCED SEPARATION OF RARE EARTH METALS | Seren Technologies Limited (GB) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807431-A1 | RARE EARTH METAL OXIDE PREPARATION | Seren Technologies Limited (GB) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807284-A1 | IONIC LIQUID PREPARATION | Seren Technologies Limited (GB) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807430-A1 | COUNTERCURRENT RARE EARTH SEPARATION PROCESS | Seren Technologies Limited (GB) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019239149-A1 | IONIC LIQUID PREPARATION | Seren Technologies Limited (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019239150-A1 | ENHANCED SEPARATION OF RARE EARTH METALS | Seren Technologies Limited (GB) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210285072-A1 | COUNTERCURRENT RARE EARTH SEPARATION PROCESS | COIL, NAF1, SRSF9 | DNM1 628/4885TSHR 3368/4885MEN1 293/4885 |
| US-11958754-B2 | Enhanced separation of rare earth metals | CA2, CA7, SLC39A14 | DNM1 1565/4885TSHR 4438/4885MEN1 192/4885 |
| US-12024756-B2 | Countercurrent rare earth separation process | COIL, NAF1, SRSF9 | DNM1 628/4885TSHR 3368/4885MEN1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.